IP Library › Granted Patent US 12,227,755
Granted Patent B2
US 12,227,755 · App. 17/846,817 · Granted Feb 18, 2025

Replication-defective arenavirus vectors

Inventors: Daniel D. Pinschewer (Binningen, CH); Lukas Flatz (Schaan, LI); Andreas Bergthaler (Gmunden, AT); Rolf Zinkernagel (Zumikon, CH)
Assignee: UNIVERSITÄT ZÜRICH
C12N15/86A61K35/76A61K39/12C07K14/005C12N7/00A61K2039/525A61K2039/5256C12N2760/10032C12N2760/10034C12N2760/10043C12N2760/10061C12N2830/008C12N2840/203C12N2840/206Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,227,755
App. No.
17/846,817
Granted
Feb 18, 2025
Kind
B2
Abstract

The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II or RNA polymerase III. The modified arenaviruses are useful as vaccines and therapeutic agents for a variety of diseases.

Claims (10)

1. A method of making a recombinant cell comprising transfecting a cell with plasmids encoding for intracellular expression of transacting factors (TF-plasmids), and plasmids encoding arenavirus vector genome segments (GS-plasmids),

wherein the GS-plasmid encodes a large segment of the arenavirus genome (L segment) or a small segment of the arenavirus genome (S segment),

wherein the GS-plasmid encoding the S segment comprises an arenavirus open reading frame wherein a sequence encoding for glycoprotein (GP) is removed and replaced by a foreign ribonucleic acid sequence,

wherein the foreign ribonucleic acid sequence encodes for (a) a viral antigen selected from a hepatitis B antigen, a respiratory syncytial virus antigen, a human immunodeficiency virus antigen, an influenza antigen, a hepatitis C virus antigen, a varicella zoster virus antigen, a herpes simplex virus antigen, or a cytomegalovirus antigen; (b) a bacterial antigen selected from a Haemophilus spp. antigen, a Pneumoccoccus spp. antigen, or a Mycobacterium tuberculosis antigen; (c) a parasite antigen selected from the group consisting of a plasmodia antigen, an amebia antigen, and a philaria antigen; or (d) a tumor antigen.

2. The method of claim 1 , wherein the TF plasmid encodes for intracellular expression of a viral trans-acting factor.

3. The method of claim 2 , wherein the viral trans-acting factor is a nucleoprotein (NP) or an RNA-dependent RNA polymerase (L protein).

4. The method of claim 3 , wherein the cell is transfected with a TF-plasmid comprising an open reading frame encoding for intracellular expression of NP, a TF-plasmid comprising an open reading frame encoding for intracellular expression of L protein, or both.

5. The method of claim 1 , wherein the cell is further transfected with a complementing plasmid (C-plasmid) encoding for intracellular expression of glycoprotein (GP).

6. The method of claim 1 , wherein the cell is a complementing cell and stably expresses the glycoprotein (GP).

7. The method of claim 1 , wherein the cell is transfected with a GS-plasmid encoding the L segment, a GS-plasmid encoding the S segment, or both.

Priority Claims (1)
EP 07025099 · Dec 27, 2007 · regional
Continuity (6)
Continuation 16861758 · Apr 29, 2020
Division 15928003 · Mar 21, 2018
Continuation 15069773 · Mar 14, 2016
Continuation 14061025 · Oct 23, 2013
Continuation 12810382
Related Publication 20220315951A1 · Oct 6, 2022
References Cited (112)
US 5789245A · Dubensky et al. · 1998 [cited by applicant]
US 6440730B1 · Von Laer et al. · 2002 [cited by applicant]
US 8592205B2 · Pinschewer et al. · 2013 [cited by applicant]
US 9309289B2 · Pinschewer et al. · 2016 [cited by applicant]
US 9809801B2 · Belnoue et al. · 2017 [cited by applicant]
US 9944952B2 · Pinschewer et al. · 2018 [cited by applicant]
US 10111945B2 · Orlinger et al. · 2018 [cited by applicant]
US 10655145B2 · Pinschewer et al. · 2020 [cited by applicant]
US 10669315B2 · Orlinger et al. · 2020 [cited by applicant]
US 10722564B2 · Pinschewer et al. · 2020 [cited by applicant]
US 11266727B2 · Schmidt et al. · 2022 [cited by applicant]
US 11214598B2 · Monath et al. · 2022 [cited by applicant]
US 11401528B2 · Pinschewer et al. · 2022 [cited by applicant]
US 11407790B2 · Orlinger et al. · 2022 [cited by applicant]
US 11554169B2 · Orlinger et al. · 2023 [cited by applicant]
US 20050052172A1 · Schripsema et al. · 2005 [cited by applicant]
US 20050123517A1 · McCray et al. · 2005 [cited by applicant]
US 20070005929A1 · Post et al. · 2007 [cited by applicant]
US 20090041725A1 · Neubert et al. · 2009 [cited by applicant]
US 20100297172A1 · Pinschewer et al. · 2010 [cited by applicant]
US 20140050760A1 · Pinschewer et al. · 2014 [cited by applicant]
US 20160024476A1 · Belnoue et al. · 2016 [cited by applicant]
US 20160194663A1 · Pinschewer et al. · 2016 [cited by applicant]
US 20160296619A1 · Orlinger et al. · 2016 [cited by applicant]
US 20170319673A1 · Pinschewer et al. · 2017 [cited by applicant]
US 20180179257A1 · Orlinger et al. · 2018 [cited by applicant]
US 20180319845A1 · Monath et al. · 2018 [cited by applicant]
US 20180344830A1 · Schmidt et al. · 2018 [cited by applicant]
US 20190062784A1 · Pinschewer et al. · 2019 [cited by applicant]
US 20190135875A1 · Bonilla et al. · 2019 [cited by applicant]
US 20190247493A1 · Orlinger et al. · 2019 [cited by applicant]
US 20200113995A1 · Orlinger et al. · 2020 [cited by applicant]
US 20200206334A1 · Schmidt et al. · 2020 [cited by applicant]
US 20210024584A1 · Orlinger et al. · 2021 [cited by applicant]
US 20210071198A1 · Pinschewer et al. · 2021 [cited by applicant]
US 20210145950A1 · Pinschewer et al. · 2021 [cited by applicant]
US 20220073568A1 · Monath et al. · 2022 [cited by applicant]
US 20220257734A1 · Schmidt et al. · 2022 [cited by applicant]
US 20220289797A1 · Bonilla et al. · 2022 [cited by applicant]
US 20220380805A1 · Pinschewer et al. · 2022 [cited by applicant]
US 20230086859A1 · Orlinger et al. · 2023 [cited by applicant]
US 20230181725A1 · Orlinger et al. · 2023 [cited by applicant]
EP 1156118 · 2001 [cited by applicant]
EP 1012295 · 2004 [cited by applicant]
EP 1608393 · 2012 [cited by applicant]
WO WO2005061534 · 2005 [cited by applicant]
WO WO2006053871 · 2006 [cited by applicant]
WO WO2006084746 · 2006 [cited by applicant]
WO WO2009083210 · 2009 [cited by applicant]
WO WO2012093340 · 2012 [cited by applicant]
WO WO2014140301 · 2014 [cited by applicant]
WO WO2015082570 · 2015 [cited by applicant]
WO WO2016075250 · 2016 [cited by applicant]
WO WO2016198531 · 2016 [cited by applicant]
WO WO2017076988 · 2017 [cited by applicant]
WO WO2017080920 · 2017 [cited by applicant]
WO WO2017198726 · 2017 [cited by applicant]
WO WO2018083220 · 2018 [cited by applicant]
WO WO2018185307 · 2018 [cited by applicant]
WO WO2021089853 · 2021 [cited by applicant]
WO WO2021239471 · 2021 [cited by applicant]
WO WO2022200373 · 2022 [cited by applicant]
Flatz et al. Proc Natl Acad Sci U S A. Mar. 21, 2006; 103(12): 4663-4668. [cited by examiner]
Mar Perez et al. PNAS published by Oct. 16, 2003, vol. 100 (22), pp. 12978-12983. [cited by examiner]
Abel et al., 2010, “The Novel Tuberculosis Vaccine, AERAS-402, Induces Robust and Polyfunctional CD4+ and CD8+ T Cells in Adults,” American Journal of Respiratory and Critical Care Medicine, 181(12):1407-1417. [cited by applicant]
Atreya et al., 1998, “The NS1 Protein of Human Respiratory Syncytial Virus Is a Potent Inhibitor of Minigenome Transcription and RNA Replication,” Journal of Virology, 72(2):1452-1461. [cited by applicant]
Bergthaler et al., 2007, “Contributions of the lymphocytic choriomeningitis virus glycoprotein and polymerase to strain-specific differences in murine liver pathogenicity,” Journal of General Virology, 88(2):592-603. [cited by applicant]
Bergthaler et al., 2006, “Envelope exchange for the generation of live-attenuated arenavirus vaccines,” PLOS Pathogens, 2(6):501-512. [cited by applicant]
Bitzer et al., 2003, “Sendai virus vectors as an emerging negative-strand RNA viral vector system,” The Journal of Gene Medicine, 5(7):543-553. [cited by applicant]
Buchmeier et al., 2007, “Arenaviridae: the viruses and their replication,” Fields Virology; Philadelphia, PA, USA: Wolter Kluwer Lippincott Williams & Wilkins, 2:1791-1827. [cited by applicant]
Cardin et al., 2016, “Replication-defective lymphocytic choriomeningitis virus vectorsexpressing guinea pig cytomegalovirus GB and pp65 homologs areprotective against congenital guinea pig cytomegalovirus infection,” Va… [cited by applicant]
Cornu et al., 2001, “RING finger Z protein of lymphocytic choriomeningitis virus (LCMV) inhibits transcription and RNA replication of an LCMV S-segment minigenome,” Journal of Virology, 75(19):9415-9426. [cited by applicant]
Dudek and Knipe, 2006, “Replication-defective viruses as vaccines and vaccine vectors,” Virology, 344:230-239. [cited by applicant]
Flatz et al., 2010, “Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity,” Nature Medicine, 16(3):339-345. [cited by applicant]
Flatz et al., 2012, “Gene-Based Vaccination with a Mismatched Envelope Protects against Simian Immunodeficiency Virus Infection in Nonhuman Primates,” Journal of Virology, 86(15):7760-7770. [cited by applicant]
Flatz et al., 2006, “Recovery of an arenavirus entirely from RNA polymerase I/II-driven cDNA,” The Proceedings of the National Academy of Sciences (PNAS), 103(12):4663-4668. [cited by applicant]
Flatz et al., 2011, “Single-cell gene-expression profiling reveals qualitatively distinct CD8 T cells elicited by different gene-based vaccines,” The Proceedings of the National Academy of Sciences (PNAS), 108(14):5724-… [cited by applicant]
Hass et al., 2004, “Replicon system for Lassa virus,” Journal of Virology, 78(24):13793-13803. [cited by applicant]
ICTV Virus Taxonomy, Virus Taxonomy: 2005 Release, ICTV 8th Report (MSL #23) [online] [retrieved on Feb. 17, 2016] Retrieved from the Internet: http://www.ictvonline.org/virusTaxonomy.asp?msl_id=23. [cited by applicant]
International Search Report and Written Opinion dated Apr. 6, 2009 for PCT/EP2008/010994 (11 pages). [cited by applicant]
Karkhanis et al., 2007, “Mucosal vaccine vectors: replication-competent versus replication-deficient poxviruses,” Current Pharmaceutical Design, 13:2015-2023. [cited by applicant]
Kunz et al., 2005, “Novel antiviral strategies to combat human arenavirus infections,” Current Molecular Medicine, 5:735-751. [cited by applicant]
Lee et al., 2000, “NP and L proteins of lymphocytic choriomeningitis virus (LCMV) are sufficient for efficient transcription and replication of LCMV genomic RNA analogs,” Journal of Virology, 74(8):3470-3477. [cited by applicant]
Lee et al., 2002, “Identification of the lymphocytic choriomeningitis virus (LCMV) proteins required to rescue LCMV RNA analogs into LCMV-like particles,” Journal of Virology, 76(12):6393-6397. [cited by applicant]
Leist et al., 1988, “Virus-triggered immune suppression in mice caused by virus-specific cytotoxic T cells,” Journal of Experimental Medicine, 167:1749-1754. [cited by applicant]
Liljeström and Garoff, 2001, “Expression of proteins using Semliki Forest virus vectors,” Current Protocols in Molecular Biology, 29(1994):16.20.1-16.20.16. [cited by applicant]
Loera-Arias et al., 2009, “Targeting and Retention of HPV16 E7 to the Endoplasmic Reticulum Enhances Immune Tumour Protection,” Journal of Cellular and Molecular Medicine, 14(4):890-894. [cited by applicant]
Lundstrom, 2002, “Alphavirus-based vaccines,” Current Opinion in Molecular Therapeutics, 4(1):28-34. [cited by applicant]
Lundstrom, 2005, “Biology and application of alphaviruses in gene therapy,” Gene Therapy, 12:S92-S97. [cited by applicant]
Merkler et al., 2006, “Viral déjà vu elicits organ-specific immune disease independent of reactivity to self,” The Journal of Clinical Investigation, 116(5):1254-1263. [cited by applicant]
Mueller et al., 2007, “Viral targeting of fibroblastic reticular cells contributes to immunosuppression and persistence during chronic infection,” The Proceedings of the National Academy of Sciences (PNAS), 104(39):1543… [cited by applicant]
Perez et al., 2004, “Myristoylation of the RING finger Z protein is essential for arenavirus budding,” Journal of Virology, 78(20):11443-11448. [cited by applicant]
Perez et al., 2003, “The small RING finger protein Z drives arenavirus budding: implications for antiviral strategies,” The Proceedings of the National Academy of Sciences (PNAS), 100(22):12978-12983. [cited by applicant]
Pinschewer et al., 2005, “Dual role of the lymphocytic choriomeningitis virus intergenic region in transcription termination and virus propagation,” Journal of Virology, 79(7):4519-4526. [cited by applicant]
Pinschewer et al., 2004, “Kinetics of protective antibodies are determined by the viral surface antigen,” The Journal of Clinical Investigation, 114(7):988-993. [cited by applicant]
Pinschewer et al., 2003, “Role of the virus nucleoprotein in the regulation of lymphocytic choriomeningitis virus transcription and RNA replication,” Journal of Virology, 77(6):3882-3887. [cited by applicant]
Pinschewer et al., 2003, “Recombinant lymphocytic choriomeningitis virus expressing vesicular stomatitis virus glycoprotein,” The Proceedings of the National Academy of Sciences (PNAS), 100(13):7895-7900. [cited by applicant]
Pinschewer et al., 2003, “Recombinant lymphocytic choriomeningitis virus expressing vesicular stomatitis virus glycoprotein,” The Proceedings of the National Academy of Sciences (PNAS), 100(13):Supporting Figure 4. [cited by applicant]
Plotkin, 2008, “Determinants of Memory T cell Responses,” Vaccines 5 [cited by applicant]
Plotkin, 2008, “Mumps vaccine,” Vaccines, 5 [cited by applicant]
Plotkin, 2008, “Rubella vaccine,” Vaccines, 5 [cited by applicant]
Polo et al., 2002, “Virus-based vectors for human vaccine applications,” Drug Discovery Today, 7(13):719-727. [cited by applicant]
Querec et al., 2009, “Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,” Nature Immunology, 10(1):116-125. [cited by applicant]
Radoshitzky et al., 2015, “Past, present, and future of arenavirus taxonomy,” Archives of Virology, 160:1851-1874. [cited by applicant]
Sanchez et al., 2006, “Rescue of the prototypic Arenavirus LCMV entirely from plasmid,” Virology, 350(2):370-380. [cited by applicant]
Takeda et al., 2003, “Protective efficacy of an AIDS vaccine, a single DNA priming followed by a single booster with a recombinant replication-defective sendai virus vector, in a macaque AIDS model,” Journal of Virology… [cited by applicant]
Third Party Observation, dated May 17, 2013, in European Application No. 08868316.4 (European National Stage of PCT/EP2008/010994). [cited by applicant]
Tibbetts et al., 2003, “Establishment and maintenance of gammaherpesvirus latency are independent of infective dose and route of infection,” Journal of Virology, 77(13):7696-7701. [cited by applicant]
Watanabe et al., 2003, “Exploitation of Nucleic Acid Packaging Signals To Generate a Novel Influenza Virus-Based Vector Stably Expressing Two Foreign Genes,” Journal of Virology, 77(19):10575-10583. [cited by applicant]
Watanabe et al., 2002, “Immunogenicity and protective efficacy of replication-incompetent influenza virus-like particles,” Journal of Virology, 76(2):767-773. [cited by applicant]
Yee et al., 1994, “A general method for the generation of high-titer, pantropic retroviral vectors: Highly efficient infection of primary hepatocytes,” The Proceedings of the National Academy of Sciences (PNAS), 91:9564… [cited by applicant]
Zinkernagel, 2002,“Immunity, immunopathology and vaccines against HIV” Vaccine, 20:1913-1917. [cited by applicant]